Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Aartselaar – page 92

2 143 clinical trials in Aartselaar, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Aartselaar at a glance
2 143
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 143 trials in Aartselaar

Open in trial search

B-cell lymphoma

Not recruiting

Study of Glofitamab, Atezolizumab, and Polatuzumab Vedotin for Adults with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Pulmonary sarcoidosis

Not recruiting

Study on the Effects and Safety of Namilumab for Patients with Chronic Lung Sarcoidosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Namilumab
  • Sponsor:Kinevant Sciences GmbH

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Golimumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Study of Imetelstat in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Refractory to Erythropoiesis-Stimulating Agents

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imetelstat Sodium
  • Sponsor:Geron Corp.

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Fungal infection

Not recruiting

Study on Rezafungin to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fluconazole
  • Sponsor:Mundipharma Research Limited

Study of Tepotinib and Osimertinib for Patients with Advanced or Metastatic Lung Cancer Resistant to Osimertinib Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Merck Healthcare KGaA

Study of Tepotinib for Patients with Advanced Lung Cancer with MET Exon 14 Skipping Alterations or MET Amplification

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tepotinib
  • Sponsor:Merck Healthcare KGaA

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with a Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of 19CP02 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:19Cp02
  • Sponsor:Lakefront Biotherapeutics

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Aartselaar

What the registry says about research in the country

01 Infectious Disease Research

Pioneering research examining SARS-CoV-2 immunity patterns in immunocompromised populations, focusing on long-term antibody responses to viral variants.

  • Immunity Monitoring
  • Vulnerable Populations
  • Antibody Response Assessment

This study specifically includes nursing home residents, dialysis patients, and transplant recipients aged 18-105.

02 Viral Infection Treatment

Clinical evaluation of novel therapeutic approaches for managing Epstein-Barr Virus infections, with a focus on reducing fatigue symptoms.

  • Fatigue Management
  • Treatment Efficacy
  • Symptom Control

The research employs a rigorous double-blind methodology to assess treatment effectiveness against asthenia.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.